HomeStock SectorsBioTechWhat To Expect From...

What To Expect From Eli Lilly’s Q2 Earnings – Eli Lilly (NYSE:LLY)

Eli Lilly and Co. LLY is set to release its second-quarter earnings on August 7. According to Benzinga Pro data, analysts are anticipating adjusted earnings of $5.56 per share and sales of $14.4 billion.

Expectations are slightly higher for the quarter, primarily driven by the strong performance of its obesity drug, Zepbound. The pharmaceutical giant, a dominant player in the incretin/GLP-1 drug market for obesity and diabetes, continues to draw investor attention with its robust pipeline and long-term growth prospects.

Analyst Adjustments and Forecasts

Ahead of the earnings release, Bank of America Securities (BofA) has made minor adjustments to its earnings model for Eli Lilly.

Also Read: FDA Approves New Dosing Schedule For Eli Lilly’s Kisunla In Alzheimer’s Treatment

BofA analyst Tim Anderson specifically noted a slight, low single-digit percentage increase in second-quarter revenue and EPS forecasts, primarily driven by stronger anticipated sales of Zepbound.

Looking further out, the analyst updated full-year projections, expecting total revenue to rise by 1% and 0.4% in 2025, with EPS growing by 1.9% in 2025 but experiencing a slight dip of 0.7% in 2026.

Beyond 2026, revenue and EPS projections largely remain consistent. Importantly, long-term forecasts for Lilly’s key products, Mounjaro, Zepbound, orforglipron, and retatrutide, have not seen significant revisions.

BofA Maintains Buy Rating

BofA maintains a Buy rating on Eli Lilly, with a price forecast of $1,000. This reflects the firm’s view of Lilly’s exceptional and sustainable growth potential compared to its peers, at what is considered a reasonable valuation.

The core focus of the company remains its incretin/GLP-1 drugs for obesity and diabetes, a market where Lilly is expected to maintain a leading position in the foreseeable future alongside one other top company.

Key Focus Areas for the Earnings Call

The earnings call will focus on several key areas. Broader concerns around U.S. drug pricing changes, including the ‘most favored nation’ proposal and possible pharma-related tariffs under Section 232, are expected to be discussed.

Important upcoming clinical trial results, such as tirzepatide’s SURPASS-CVOT, orforglipron’s ATTAIN-1, and Novo Nordisk A/S’ NVO REDEFINE-4, will also be a point of interest.

Performance updates on major products, especially Mounjaro and Zepbound, will be closely watched. Additionally, early launch progress for new drugs like Kisunla for Alzheimer’s and Ebglyss for eczema will be highlighted.

Price Action: LLY stock is trading higher by 0.82% to $784.07 at last check Wednesday.

Read Next:

Photo via Shutterstock

Most Popular

More from Author

What To Expect From Johnson & Johnson’s Q2 Earnings – Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson JNJ is set to release its second-quarter earnings...

Why Is Kazia Stock Soaring Today – Kazia Therapeutics (NASDAQ:KZIA)

Kazia Therapeutics KZIA on Wednesday reported preliminary results from the first...

Amazon, Defense Stocks in Spotlight Amid Trade and Consumer Uncertainty

US stocks are modestly higher as investors weigh up the latest...

Read Now

Massive 69.4% Surge for IGC Pharma in After-Hours Trading: Here’s Why – IGC Pharma (AMEX:IGC)

IGC Pharma Inc IGC witnessed a surge of 69.40%  in its stock value during after-hours trading on Wednesday.What Happened: The stock of IGC Pharma, a company involved in the development of cannabinoid-based therapies for Alzheimer‘s disease, rose by 69.40% to $0.62. This surge followed the closing price...

What To Expect From Johnson & Johnson’s Q2 Earnings – Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson JNJ is set to release its second-quarter earnings on Wednesday, July 16. According to Benzinga Pro data, analysts estimate adjusted earnings of $2.68 per share and sales of $22.85 billion.While overall estimates for 2025 and beyond show only slight increases, investor attention is expected...

Why Is Kazia Stock Soaring Today – Kazia Therapeutics (NASDAQ:KZIA)

Kazia Therapeutics KZIA on Wednesday reported preliminary results from the first patient in its Phase 1b trial evaluating a combination regimen of Paxalisib, Merck & Co Inc’s MRK Keytruda (pembrolizumab), and standard chemotherapy after completing Cycle 1 (21 days) of dosing.The patient, a 61-year-old woman with metastatic...

Amazon, Defense Stocks in Spotlight Amid Trade and Consumer Uncertainty

US stocks are modestly higher as investors weigh up the latest announcements from President Trump and watch for further trade developments. President Trump announced plans to impose 50% tariffs on imports, sending prices sharply higher. US copper prices shot 13% higher, closing at a record high of...

Rhythm Pharma’s Oral Drug For Rare Obesity Shows Promise – Rhythm Pharmaceuticals (NASDAQ:RYTM)

Rhythm Pharmaceuticals, Inc. RYTM on Wednesday released topline results from its Phase 2 trial evaluating bivamelagon (formerly LB54640), an investigational oral melanocortin-4 receptor (MC4R) agonist, in patients with acquired hypothalamic obesity.Hypothalamic obesity is a rare type of obesity resulting from damage to the hypothalamus, a brain region...

Risk Assets Rebound as Trump Pushes Tariff Deadline to August 1

After a volatile past day session, this one was way calmer as Trump announced yet another delay in tariff deadlines – From the approaching July 9th to August 1st, apparently the final warning. The session began with the leading to the upside, followed by general mean-reversion all...

Gilead’s Lenacapavir Plan Faces Global Hurdles As It Commits To No-Profit Access for 2 Million – Gilead Sciences (NASDAQ:GILD)

Gilead Sciences, Inc. GILD on Wednesday announced a strategic partnership agreement with the Global Fund to Fight AIDS, Tuberculosis and Malaria to supply lenacapavir — Gilead’s twice-yearly injectable HIV-1 capsid inhibitor — for the prevention of HIV as pre-exposure prophylaxis (PrEP).Through the agreement, Gilead will supply enough...

Markets Today: RBNZ Rate Hold, Copper Volatility, DAX Moves Toward Fresh Highs

Chinese stocks are set to hit their highest level in three years as investors hope for new steps to fight deflation and boost the economy. Meanwhile, dropped in London after President Donald Trump issued a new tariff warning.Asian Market WrapThe Shanghai Stock Exchange Composite Index rose...

FDA Approves New Dosing Schedule For Eli Lilly’s Kisunla In Alzheimer’s Treatment – Eli Lilly (NYSE:LLY)

The U.S. Food and Drug Administration (FDA) has approved a label update with a new recommended titration dosing schedule for Eli Lilly and Co.’s LLY Kisunla (donanemab-azbt) once-monthly amyloid-targeting therapy for adults with early symptomatic Alzheimer’s disease (AD). The FDA approved the drug in July 2024.In the TRAILBLAZER-ALZ 6...

H2 2025: Room for Optimism, Risk for Complacency

Reasons To Be Fearful, Reasons To Be Cheerful It was an eventful first half of the year, to say the least... In January, the rise of DeepSeek was a wake-up call for the world, demonstrating that China is a major competitor to the US in AI and technology. The...

Merck Strikes $10-Billion Deal For Verona, Secures First-In-Class COPD Drug – Merck & Co (NYSE:MRK), Verona Pharma (NASDAQ:VRNA)

Merck & Co. Inc. MRK agreed on Wednesday to acquire Verona Pharma plc VRNA for $107 per American Depository Share (ADS) for a total transaction value of approximately $10 billion. Each ADS represents eight ordinary shares of Verona Pharma.Through the acquisition of this respiratory disease-focused company, Merck...

The Energy Report: Demand Exceeding Supply

It’s the oldest story in the book. Prices go up when demand exceeds supply, not only in oil and products but in wholesale power, driving up electricity costs. The Energy Information Administration (EIA) in its Short-Term Energy Outlook confirmed that we have a global supply deficit. Not only...